Jalili, M., Yaghmaie, M., Ahmadvand, M., Alimoghadam, K., Mousavi, S., Vaezi, M., Ghavamzadeh, A. (2018). Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 19(2), 325-329. doi: 10.22034/APJCP.2018.19.2.325
Mahdi Jalili; Marjan Yaghmaie; Mohammad Ahmadvand; Kamran Alimoghadam; Seyed Asadollah Mousavi; Mohammad Vaezi; Ardeshir Ghavamzadeh. "Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis". Asian Pacific Journal of Cancer Prevention, 19, 2, 2018, 325-329. doi: 10.22034/APJCP.2018.19.2.325
Jalili, M., Yaghmaie, M., Ahmadvand, M., Alimoghadam, K., Mousavi, S., Vaezi, M., Ghavamzadeh, A. (2018). 'Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis', Asian Pacific Journal of Cancer Prevention, 19(2), pp. 325-329. doi: 10.22034/APJCP.2018.19.2.325
Jalili, M., Yaghmaie, M., Ahmadvand, M., Alimoghadam, K., Mousavi, S., Vaezi, M., Ghavamzadeh, A. Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2018; 19(2): 325-329. doi: 10.22034/APJCP.2018.19.2.325
Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis
1Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
2Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Receive Date: 03 October 2017,
Revise Date: 11 November 2017,
Accept Date: 16 December 2017
Abstract
The RUNX1 (AML1) gene is a relatively infrequent mutational target in cases of acute myeloid leukemia (AML). Previous work indicated that RUNX1 mutations can have pathological and prognostic implications. To evaluate prognostic value, we conducted a meta-analysis of 4 previous published works with data for survival according to RUNX1 mutation status. Pooled hazard ratios for overall survival and disease-free survival were 1.55 (95% confidence interval (CI) = 1.11–2.15; p-value = 0.01) and 1.76 (95% CI = 1.24–2.52; p-value = 0.002), respectively, for cases positive for RUNX1 mutations. This evidence supports clinical implications of RUNX1 mutations in the development and progression of AML cases and points to the possibility of a distinct category within the newer WHO classification. Though it must be kept in mind that the present work was based on data extracted from observational studies, the findings suggest that the RUNX1 status can contribute to risk-stratification and decision-making in management of AML.
Top